
Overview
Proacta is a leader in bioinformatics and artificial intelligence-based medicine, providing advanced predictive models and data analysis tailored to the healthcare sector. The company specializes in revolutionary medical technologies that enhance the quality and efficiency of healthcare, as well as dedicated software solutions that support clinical decision-making and patient data management. Proacta also focuses on optimizing medical processes and personalizing therapies through the use of AI and machine learning.
- Skromna 3, 20-704 Lublin
Financials
Revenue history (in k)
Filing timeliness
1 of 6 financial statements was filed late (for 2024, 66 days late). All were audited by a statutory auditor.
- 202509/07/2026
- 202419/09/2025
- 202313/07/2024
- 202204/07/2023
- 202106/07/2022
- 202002/07/2021
Data and insights are generated automatically from financial statements – they may contain errors and are neither a credit assessment nor business advice.
Stock quotes
- Open
- PLN 1.36
- High
- PLN 1.39
- Low
- PLN 1.23
- Volume
- 32.1K
- Avg. vol.
- 17.19K
- Market cap
- PLN 144.43M
- P/E ratio
- 123.00
- EPS
- PLN 0.01
- Shares outstanding
- 117.43M
- 52-week
- PLN 1.21 – 1.45
- Dividend yield
- –
- Dividend
- –
- Ex dividend date
- –
- ISIN
- PLBTEVL00019
- Exchange
- NewConnect
Quarterly results
| Period | Revenue | EBIT | Net profit |
|---|---|---|---|
| Q2 2026 | USD 551.32k | USD -105.89k | USD -44.84k |
| Q1 2026 | USD 1.67m | USD 492.17k | USD 488.38k |
| Q4 2025 | USD 925.41k | USD -130.09k | USD -159.47k |
| Q3 2025 | USD 1.19m | USD 377.45k | USD 359.37k |
Statistics
How the company ranks by revenue within its industry, city, voivodeship and across Poland in 2025.
Results vs industry
News
Proacta strengthens strategic competencies
Proacta S.A. appoints a Medical Advisory Board supporting the development of certified medical devices
Proacta SA signs a letter of intent with VeritaMed – a step towards commercialization of the „Dbam o Siebie” platform

Artificial intelligence in the fight against cervical cancer – Proacta team publication in a prestigious scientific journal
Estimated revenues of Proacta SA for Q1 2026
Proacta begins commercialization of the DBCU platform
Industry
Offer
- Medical data analysis
- Predictive models
- Medical software
- Medtech solutions
- Clinical decision support tools
- R&D project support
Websites
The sites are available in: Polish and English.
- proacta.plProacta – Proacta.plWordPress 7.1Google AnalyticsGoogle Tag ManagerWWPMLCloudflare
- dbamosiebie.plDbam o siebie - zdrowie mam we krwi - analiza wyników badańWooCommerce 10.7WordPress 7.1Google Tag ManagerYoast SEOCloudflare
- vespace.plVE SPACE – Wirtualne konferencje, targi, wystawyGoogle AnalyticsGoogle Tag ManagerMeta PixelCloudflareApache
Public procurement
No recorded participation in tenders.
Proacta has been a party to 1 case before the National Appeal Chamber (since 2024).
| Date | Subject of dispute | Outcome | Other party | |
|---|---|---|---|---|
| Apr 23, 2024 | Order | Discontinued | Skarb Państwa – Centralny Ośrodek Informatyki |
Job offers
The company has its own careers page: proacta.pl.
Authorized Representatives
Manner of representation
Making declarations of will on behalf of the company requires the joint action of two members of the management board or one member of the management board jointly with a commercial proxy.
Supervisory board
Beneficial owners
Proacta is a public company listed on NewConnect, so it does not report beneficial owners to the CRBR (Art. 58 of the Polish AML Act). Its shareholders are disclosed in stock-exchange reports.
Subsidiaries
Bank accounts
Registered as a VAT taxpayer on 2015-08-21.
Debt
No entries in the National Debtors Register (KRZ).
MSiG notices
| Publication date | Event | |
|---|---|---|
| Jun 13, 2024 | Commercial Companies Code notice |
Public aid
8 public aid cases recorded, with a total value of $1,016,982.
| Grant date | Purpose | Gross amount | Granting body | |
|---|---|---|---|---|
| Jan 16, 2026 | De minimis aid (in accordance with Commission Regulation 2023/2831) | $3,025$3,025 | Prezes Banku Gospodarstwa Krajowego | |
| May 22, 2025 | De minimis aid (in accordance with Commission Regulation 2023/2831) | $3,899$3,899 | Prezes Zakładu Ubezpieczeń Społecznych | |
| Apr 22, 2025 | Aid for research and development projects: industrial research | $609.8K$609,800 | Prezes Agencji Badań Medycznych |
Competitors
| Name | Revenue | Website | ||
|---|---|---|---|---|
| Dataserve S.A. | $8,957,118.80 | dataserve.eu | ||
| SCS Expert sp. z o.o. | $8,257,156.45 | scsexpert.com | ||
| Addepto sp. z o.o. | $5,333,694.00 | addepto.com | ||
| Algomine Group sp. z o.o. | $3,923,326.94 | algomine.pl | ||
| Statsoft Polska sp. z o.o. | $3,340,474.34 | statsoft.pl | ||
| Transition Technologies-Science sp. z o.o. | $3,266,337.95 | ttsi.com.pl | ||
| Medplace.Pl sp. z o.o. | $1,248,874.05 | medplace.pl | ||
| Alcid sp. z o.o. | $1,230,813.28 | alcid.pl | ||
| Saventic Health sp. z o.o. | $1,089,246.05 | saventic.com | ||
| Precisionlife Poland sp. z o.o. | $617,020.34 | precisionlife.com |
Change history
| Date | Event | |
|---|---|---|
| 2025-07-18 | Switch to PKD 2025 (7 PKD 2007 codes → 7 PKD 2025 codes) | |
| 2024-09-12 | Share capital increase (56,687,947.00 PLN → 58,712,516.50 PLN) | |
| 2024-02-19 | Share capital increase (55,147,947.00 PLN → 56,687,947.00 PLN) | |
| 2023-09-21 | Share capital increase (3,935,665.00 PLN → 55,147,947.00 PLN) | |
| 2023-07-28 | Address change (Ul. Wierzbięcice 44a/40a, 61-568, Poznań → Ul. Srebrna 16, 00-810, Warszawa) |
FAQ
Last updated: 2026-10-03
